Skip to main
  1. Stocks
  2. Immix Biopharma
  3. Forecast
IMMX

Immix Biopharma (IMMX) Stock Forecast & Price Target

Immix Biopharma (IMMX) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 57%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Immix Biopharma is supported by a compelling clinical thesis, as NXC-201 has shown an 89% complete response rate across 45 patients, with 100% cardiac responses and 92% organ responses among evaluable patients, while safety remains manageable with no relapses reported and no new grade ≥3 CRS, ICANS, or high-grade cardiac events. The company’s near-term value is further reinforced by visible regulatory and commercial catalysts, including a data update from the NEXICART-2 trial, planned BLA submission to the FDA in 1H27 or mid-2027, Phase 3 initiation in 1H:27 or 2H27, and a potential U.S. launch in r/r AL amyloidosis in 2028. Financially, Immix ended 2Q26 with ~$234.2M in cash and 3Q26 with ~$340.9M, implying runway into mid-2028, while disciplined expense control and rising conviction in accelerated approval support the positive outlook.

Bears say

Immix Biopharma is viewed pessimistically because its lead CAR-T candidate NXC-201 faces meaningful clinical risk, including potential safety problems such as Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome, with no assurance of a tolerable profile or success in the clinic. Regulatory risk is also elevated because none of its drugs have been approved by the FDA, filing dates could slip, and evolving requirements may delay development and approval, while competition from multiple CAR-T and bispecific T-cell engager programs could further pressure differentiation. Commercially and financially, high CAR-T costs may limit payer reimbursement and market access, production may not meet demand, and the company is likely to need additional capital for commercial trials and launch without certainty of favorable financing.

Immix Biopharma (IMMX) has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 57% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Immix Biopharma and is not a guaranteed prediction by Public.com or investment advice.

Immix Biopharma (IMMX) Analyst Forecast & Price Prediction

Get the latest Immix Biopharma (IMMX) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Immix Biopharma (IMMX)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Immix Biopharma (IMMX) Forecast

Analysts have given Immix Biopharma (IMMX) a Buy based on their latest research and market trends.

According to 7 analysts, Immix Biopharma (IMMX) has a Buy consensus rating as of Nov 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $24.43, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $24.43, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Immix Biopharma (IMMX)


Immix Biopharma (IMMX) Analyst Forecast & Price Prediction

Get the latest Immix Biopharma (IMMX) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Immix Biopharma (IMMX)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover IMMX stock data and trends